GlassScriptPhysician profile
Tia M Schmidt
NPI 1710688114
$1,674.63
in general payments reported to CMS, 2019-2025
21 companies · $483 in 2025
The $483 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $544 · 2024: $647 · 2025: $483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,661 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,660.74 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $361.76 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $254.75 | 2023-2025 | Airsupra, Breztri |
| Lilly USA, LLC | $140.17 | 2023-2025 | Mounjaro, Trulicity, Zepbound |
| Amgen INC. | $127.35 | 2023-2025 | Evenity, Prolia, Otezla |
| Novo Nordisk INC | $114.64 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $112.83 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $108.77 | 2023-2024 | Xarelto, Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.88 | 2023-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $46.88 | 2024-2025 | Veozah |
| Exact Sciences Corporation | $45.89 | 2023-2024 | Cologuard Collection Kit |
| Medtronic, INC. | $41.67 | 2024 | Minimed 780g |
| Dexcom, INC. | $37.97 | 2023 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $36.05 | 2024-2025 | Rexulti, Abilify Asimtufii |
| Pfizer INC. | $35.46 | 2025 | |
| Insulet Corporation | $18.55 | 2025 | Omnipod |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $18.23 | 2024 | Recorlev |
| Sanofi-Aventis U.S. LLC | $16.81 | 2024 | |
| Phathom Pharmaceuticals, INC. | $16.09 | 2025 | Voquezna |
| Halozyme INC | $15.48 | 2023 | |
| Glaxosmithkline, LLC. | $14.54 | 2024 | Shingrix, Arexvy |
| Lundbeck LLC | $13.86 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tia Schmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.